Epidermal growth factor receptor (EGFR; HER-1) is expressed in the whole epidermis of normal skin. Additionally, aberrant EGFR activity is linked to a wide range of solid tumors. Overexpression of EGFR, often combined with EGFR mutations that cause hyper-activity, are linked to rapid growth of tumor cells. As a result, EGFR and EGFR-signaling is an attractive target for more specific cancer therapies. Several anti-EGFR monoclonal antibodies have already been clinically approved. Additionally, much work on developing antibody drug conjugates and chemotherapeutic nanoparticles use EGFR as a target.
Imanis offers several EGFR-positive tumor cell line models. Natural EGFR expression in the parental cells has been confirmed by flow cytometry, and stable reporter expression in the engineered reporter cells facilitates in vivo and in vitro studies.
Cell lines endogenously expressing EGFR
Don’t see what you need in our catalog? Our scientific team engineers cell lines, viral vectors, and assays and provides as much characterization data as you need to move forward with confidence.
